Brief: Santhera Says Grants Exclusive North America License For Vamorolone To Catalyst Pharmaceuticals In Deal Valued At Up To USD 231 Mln Plus Royalties

Santhera Pharmaceuticals Holding AG

20/06/2023 06:08

June 20 (Reuters) - Santhera Pharmaceuticals Holding AG
 SANN.S :
    * SANTHERA GRANTS EXCLUSIVE NORTH AMERICA LICENSE FOR
VAMOROLONE
TO CATALYST PHARMACEUTICALS IN DEAL VALUED AT UP TO USD 231
MILLION PLUS ROYALTIES
    * SANTHERA PHARMACEUTICALS HOLDING AG  - SANTHERA WILL
RECEIVE USD
90 MLN UPFRONT AT CLOSING (USD 75 MLN IN CASH AND USD 15 MLN
EQUITY INVESTMENT)
    * SANTHERA - CATALYST MAY PAY SANTHERA SALES-BASED
MILESTONES OF
UP TO USD 105 MILLION AS WELL AS UP TO LOW-TEEN PERCENTAGE
ROYALTIES
    * SANTHERA -CATALYST WILL ASSUME CORRESPONDING THIRD-PARTY
ROYALTY
OBLIGATIONS OF SANTHERA ON VAMOROLONE SALES IN ALL INDICATIONS
IN NA
    * SANTHERA -  WILL RECEIVE ADDITIONAL USD 10 MLN UPON FDA
APPROVAL
OF VAMOROLONE PLUS USD 26 MLN TO PAY APPROVAL RELATED REGULATORY
MILESTONES 
    * SANTHERA PHARMACEUTICALS HOLDING AG  SANN.S  - NEAR-TERM
PROCEEDS FROM AGREEMENT WITH CATALYST AMOUNT TO USD 100 MLN 
    * SANTHERA PHARMACEUTICALS HOLDING AG  SANN.S  - SANTHERA
WILL
GRANT CATALYST EXCLUSIVE COMMERCIALIZATION RIGHTS TO VAMOROLONE
IN NORTH AMERICA 
    * SANTHERA PHARMACEUTICALS HOLDING AG  SANN.S  - CATALYST
MAY PAY
SANTHERA SALES-BASED MILESTONES OF UP TO USD 105 MLN

Source text for Eikon:  ID:nGNX6ZtWTp 
Further company coverage:  SANN.S 

 ((Reuters.Briefs@thomsonreuters.com;))